Evaluating chemotherapy response in pancreatic cancer using ultrasound
Prediction and Evaluation of Chemotherapy Treatment Response Using Contrast Enhanced Ultrasound in Unresected Localized Pancreatic Cancer
This study is testing if a special type of ultrasound can help doctors see how well chemotherapy is working for people with advanced pancreatic cancer after they start treatment.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 100 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Peking Union Medical College Hospital Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Beijing, Beijing) |
| Trial ID | NCT05729737 on ClinicalTrials.gov |
What this trial studies
This observational study aims to determine if contrast-enhanced ultrasound (CEUS) can predict and evaluate the early treatment response to first-line chemotherapy in patients with locally advanced and borderline resectable pancreatic cancer. Participants will undergo CEUS examinations before starting chemotherapy and after two treatment cycles to assess changes in tumor vascularity and predict treatment outcomes. The study focuses on identifying quantitative parameters from CEUS that correlate with early responses to chemotherapy, potentially guiding treatment strategies for better patient outcomes.
Who should consider this trial
Good fit: Ideal candidates are patients with histologically confirmed pancreatic ductal adenocarcinoma who are medically fit to receive first-line chemotherapy.
Not a fit: Patients with distal metastases, those refusing chemotherapy, or individuals unsuitable for CEUS, such as pregnant or lactating women, may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enable earlier and more accurate predictions of chemotherapy response, allowing for tailored treatment plans for patients with pancreatic cancer.
How similar studies have performed: Previous studies have shown promising results using CEUS to evaluate treatment responses in pancreatic cancer, indicating that this approach has potential based on prior findings.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * The main inclusion criteria were histologically proven pancreatic ductal adenocarcinoma and medical fitness for first-line chemotherapy Patients were consent to receive examinations of contrast enhanced ultrasound Exclusion Criteria: * Patients with distal metastases or patients refusing chemotherapy Patients who were not suitable for contrast-enhanced ultrasound ,such as pregnant or lactating women Patients without complete clinical data
Where this trial is running
Beijing, Beijing
- Peking Union Medical College Hospital — Beijing, Beijing, China (Recruiting)
Study contacts
- Study coordinator: Ke Lv, MD
- Email: lvke@163.com
- Phone: +8613693332479
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.